| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/12/2000 | EP0970056A1 Substituted 2-anilinopyrimidines useful as protein kinase inhibitors |
| 01/12/2000 | EP0970055A2 Hiv protease inhibitors |
| 01/12/2000 | EP0970054A1 1-(isoquinolin-1-yl)-4-(1-phenylmethyl)piperazines; dopamine receptor subtype specific ligands |
| 01/12/2000 | EP0970053A1 5-oxysubstituted chinolines and their use as cholesterol ester transfer proteins inhibitors |
| 01/12/2000 | EP0970047A1 2-alkylidene-19-nor-vitamin d compounds |
| 01/12/2000 | EP0970046A1 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 01/12/2000 | EP0970043A1 Compounds consisting in particular of effectors of the central nervous system receptors sensitive to excitatory amino acids, preparation and biological applications |
| 01/12/2000 | EP0970042A1 5-hydroxymethyl-2-aminotetralins as cardiovascular agents |
| 01/12/2000 | EP0970036A1 Aryl- and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity |
| 01/12/2000 | EP0969877A1 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 01/12/2000 | EP0969874A1 Pharmaceutical compositions containing propanamine derivatives and cyclodextrin |
| 01/12/2000 | EP0969872A2 Induction of b cell tolerance |
| 01/12/2000 | EP0969869A2 Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders |
| 01/12/2000 | EP0969868A2 Methods and kits for treating and diagnosing leiomyomas |
| 01/12/2000 | EP0969865A1 Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells |
| 01/12/2000 | EP0969864A1 Hiv p-17 peptide fragment, compositions containing and methods for producing and using same |
| 01/12/2000 | EP0969855A1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 01/12/2000 | EP0969852A1 Combination therapy for the treatment of diabetes and obesity |
| 01/12/2000 | EP0969851A1 Immunomodulatory complex and use thereof in helicobacter diseases |
| 01/12/2000 | EP0969849A1 Stable solid preparation containing vitamin d3 and tricalcium phosphate |
| 01/12/2000 | EP0969848A1 Use of diadenosine polyphosphates for reducing blood pressure |
| 01/12/2000 | EP0969847A1 Tazarotene and corticosteroid treatment for psoriasis |
| 01/12/2000 | EP0969846A1 Compositions and methods for reducing ocular hypertension |
| 01/12/2000 | EP0969845A1 New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
| 01/12/2000 | EP0969844A1 Administration of an injectable antibiotic in the ear of an animal |
| 01/12/2000 | EP0969843A2 Antitussive compositions |
| 01/12/2000 | EP0969842A1 Pharmaceutical composition |
| 01/12/2000 | EP0969841A1 Use of carboxylic acid derivatives for treating cancer |
| 01/12/2000 | EP0969840A1 Thrombin inhibitors |
| 01/12/2000 | EP0969839A1 Anhydrovinblastine for the treatment of cervical and lung cancer |
| 01/12/2000 | EP0969838A1 Product and method for the treatment of hyperlipidemia |
| 01/12/2000 | EP0969837A1 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| 01/12/2000 | EP0969836A1 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 01/12/2000 | EP0969835A1 Use of central cannabinoid receptor antagonists for regulating appetence |
| 01/12/2000 | EP0969834A1 Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent |
| 01/12/2000 | EP0969833A1 Extension of the expression of transgenic proteins by immunomodulation |
| 01/12/2000 | EP0969832A1 Pharmaceutical composition for oral administration of a n-piperidino- 3-pyrazolecarboxamide derivative, its salts and their solvates |
| 01/12/2000 | EP0969831A1 Nasal melatonin composition |
| 01/12/2000 | EP0969830A1 Drugs for memory enhancement |
| 01/12/2000 | EP0969829A1 Synthetic techniques and intermediates for polyhydroxy, dienyllactones and mimics thereof |
| 01/12/2000 | EP0969828A1 Butyrate prodrugs derived from lactic acid |
| 01/12/2000 | EP0969827A1 Mixture of primary fatty acids obtained from sugar cane wax |
| 01/12/2000 | EP0969826A1 Use of liposomes containing a chelating agent, a fungicide or a secropine for improving mucosal vaccination |
| 01/12/2000 | EP0969825A1 Pharmaceutical composition for oral administration of heterocyclic compounds in the form of quaternary ammonium |
| 01/12/2000 | EP0969824A1 Use of inhibitors of undecaprenol kinase to inhibit cell wall biosynthesis |
| 01/12/2000 | EP0969823A2 Anti-epileptogenic agents |
| 01/12/2000 | EP0969822A2 Compositions and methods for restoring a normal pattern of imprinting to cells |
| 01/12/2000 | EP0969821A1 Pellets having a core coated with an antifungal and a polymer |
| 01/12/2000 | EP0969819A2 New crystalline form of omeprazole |
| 01/12/2000 | EP0969818A1 Dosage forms comprising separate portions of r- and s-enantiomers |
| 01/12/2000 | EP0969817A1 Dosage forms having improved release properties |
| 01/12/2000 | EP0969816A1 Preparation of powder agglomerates |
| 01/12/2000 | EP0969815A2 Pharmaceutical compositions |
| 01/12/2000 | EP0969813A2 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| 01/12/2000 | EP0969812A1 Ophthalmic compositions including glycerin and propylene glycol |
| 01/12/2000 | EP0969790A2 Compositions for treating acne rosacea |
| 01/12/2000 | EP0969775A1 Bone marrow as a site for transplantation |
| 01/12/2000 | EP0969744A2 Nutritional composition for improvements in cell energetics |
| 01/12/2000 | EP0969737A1 Pet food composition |
| 01/12/2000 | EP0969720A2 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| 01/12/2000 | EP0941224A4 Multivalent salts of pyridostigmine and related compounds |
| 01/12/2000 | EP0896536B1 Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder |
| 01/12/2000 | EP0862566B1 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives |
| 01/12/2000 | EP0808307B1 Bicyclic isothiourea derivatives useful in therapy |
| 01/12/2000 | EP0781285B1 Fused indole and quinoxaline derivatives, their preparation and use as glutamate antagonists |
| 01/12/2000 | EP0781284B1 Indole-2,3-dione-3-oxime derivatives, their preparation and use |
| 01/12/2000 | EP0731698B1 Modafinil having defined particle size |
| 01/12/2000 | EP0714390B1 Indole derivatives as 5-alpha-reductase-1-inhibitors |
| 01/12/2000 | EP0693067B1 Fibrinogen receptor antagonists |
| 01/12/2000 | EP0640081B1 Substituted phenylcarbamates and phenylureas, their preparation and their use as 5-ht4 antagonists |
| 01/12/2000 | EP0604657B1 Phosphonic diester derivative |
| 01/12/2000 | EP0599968B1 Oxazolidinone derivatives useful as antiarrhythmic and antifibrillatory agents |
| 01/12/2000 | EP0584073B1 Application system for treating warts |
| 01/12/2000 | EP0559891B1 Thienodiazepine compound and its use |
| 01/12/2000 | CN1241192A Pro-drugs and counterparts of camptothecin, their application as medicines |
| 01/12/2000 | CN1241191A Counterparts of camptothecin, their application as medicine and pharmaceutical compositions contg. them |
| 01/12/2000 | CN1241189A 3-aryl-2-(1-substed.-4-piperidinyl)-1 (1-di) oxo-3H-benzo [D]-isothiazole derivs., their preparation and their use as modulators of neurotransmitter function |
| 01/12/2000 | CN1241188A Heterocyclylmethyl-substed pyrazol derivs. |
| 01/12/2000 | CN1241185A Heterocyclic substed. pyrrolidine amide derivs. |
| 01/12/2000 | CN1241184A Indole derivs. for treatment of osteoporosis |
| 01/12/2000 | CN1241183A Novel compound form |
| 01/12/2000 | CN1241181A Pharmaceutical compounds |
| 01/12/2000 | CN1241180A Method for crystallisation of tetrahydropyridin deriv. and resulting crystalline forms |
| 01/12/2000 | CN1241179A Micro-particulate form of tetrahydropyridin deriv. |
| 01/12/2000 | CN1241178A Novel compounds with analgesic effect |
| 01/12/2000 | CN1241177A Substed. 4-biphenyl-4-hydroxybutyric acid derivs. as matrix metalloprotease inhibitors |
| 01/12/2000 | CN1241176A Prevention of loss and restoration of bone mass by certain prostaglandin agonists |
| 01/12/2000 | CN1241167A Fine cisplatin powder and process for production thereof |
| 01/12/2000 | CN1241142A Pharmaceutical compositions contg. lamivudine and zidovudine |
| 01/12/2000 | CN1241141A Treatment for joint inflammation |
| 01/12/2000 | CN1241140A Therapeutic treatment for sexual dysfunctions |
| 01/12/2000 | CN1241139A Method of producing sustained-release preparation |
| 01/12/2000 | CN1241132A Dermatologic preparation |
| 01/12/2000 | CN1240790A Salts of D-fructose-1,6-bis(dihydrogen phosphate) with organic amine and pharmaceutical compositions containing them |
| 01/12/2000 | CN1240788A Acridine derivatives |
| 01/12/2000 | CN1240650A Compound metronidazole suppository |
| 01/12/2000 | CN1240649A Labor-inducing medicine |
| 01/12/2000 | CN1240648A Transition metal complexes of non steroidal anti-inflammatory drugs |
| 01/12/2000 | CN1240647A Use of calcium L-threonate in prevention and inhibition of osteoporosis and rickets |
| 01/12/2000 | CN1240646A Injectable composition of non-steroidal anti-inflammatory drugs |